60 likes | 66 Views
Statistics of Parkinsonu2019s disease therapeutics market covering market size, industry share numbers, regional outlook, competitive landscape with data about leading companies is now available in the latest report by Global Market Insights, Inc.
E N D
Parkinson’s disease therapeutics market trends research and projections for 2021- 2027 • A research study conducted by Global Market Insights, Inc., suggests that Parkinson’s disease therapeutics market is likely to exceed the $8 billion mark by 2027, in terms of revenue. • The Parkinson’s disease therapeutics market expansion would be augmented by extensive investments in R&D activities to uplift the development in the treatment of the disease. Reportedly, the Parkinson’s Foundation in 2021 invested nearly US$3.5 million in 34 research programs to support the efforts of promising scientists in the field of Parkinson’s disease (PD). • The Parkinson’s Disease Biomarkers Program (PDBP) funding endorse discovery projects to encourage the identification of developments and diagnostic biomarkers for the disease. Consequently, a substantial rise in funding towards R&D programs for the development of novel therapies will propel the demand for Parkinson’s therapeutics in the forthcoming years. © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com
The Parkinson’s disease therapeutics industry progression would further be augmented by the growing awareness among the population about the disease. Early diagnosis of the disease plays a key role in providing effective treatment to the affected patient. The lack of awareness and knowledge among people about Parkinson’s disease has led to the commencement of numerous awareness programs. • The dopamine agonists segment accounted for a considerable revenue share at nearly US$694 million in 2021. The medication is highly preferred in the treatment of Parkinson’s disease owing to its resemblance to the effect of dopamine in the brain • The adult patient segment of the Parkinson’s disease therapeutics industry is expected to grow at 6.9% CAGR up to 2027. The segment expansion is majorly attributed to the growing vulnerability to idiopathic Parkinson’s disease among the aging population base. © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com
Request for a Sample Copy of this Report @ https://www.gminsights.com/request-sample/detail/2724 © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com
Regional Analysis • The Brazil Parkinson’s disease therapeutics industry was over US$90 million in 2021. The regional industry progression is predominantly driven by robust economic expansion, substantial development in healthcare infrastructure, and rising incidences of Parkinson’s disease in the country. Also, the presence of dynamic pharmacology and biotechnology research sector backed by the Brazilian government will provide exponential growth opportunities to the regional industry. • Competitive Analysis • Leading firms functioning in the Parkinson’s disease therapeutics industry include Teva Pharmaceutical, Acadia Pharmaceuticals, AbbVie Inc., UCB, Amneal Pharmaceuticals, Roche, and Orion Corporation, among others. Request for Customization @ https://www.gminsights.com/roc/2724 © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com
Latest Research Report On Parkinson’s disease therapeutics Market @ https://www.gminsights.com/industry-analysis/parkinsons-disease-therapeutics-market Request for sample of this research report@ https://www.gminsights.com/request-sample/detail/2724 Request for customization: https://www.gminsights.com/roc/2724 © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com
Stay In Touch You can visit us at: www.gminsights.com Thank You…! © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com www.gminsights.com